MML Investors Services LLC Buys 5,260 Shares of DexCom, Inc. (NASDAQ:DXCM)

MML Investors Services LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 17.0% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 36,235 shares of the medical device company's stock after buying an additional 5,260 shares during the period. MML Investors Services LLC's holdings in DexCom were worth $2,818,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Forvis Mazars Wealth Advisors LLC increased its holdings in shares of DexCom by 0.7% during the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after acquiring an additional 118 shares in the last quarter. Principal Securities Inc. grew its position in DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock valued at $316,000 after purchasing an additional 135 shares during the last quarter. Larson Financial Group LLC increased its stake in DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Level Four Advisory Services LLC increased its stake in DexCom by 1.1% during the 4th quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after purchasing an additional 150 shares in the last quarter. Finally, Covestor Ltd raised its holdings in DexCom by 15.6% in the fourth quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock worth $86,000 after buying an additional 150 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on DXCM shares. Morgan Stanley raised their price target on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Canaccord Genuity Group increased their target price on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Redburn Atlantic upgraded DexCom from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Citigroup increased their price objective on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Finally, Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

Insiders Place Their Bets

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the company's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now owns 313,497 shares in the company, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 over the last three months. 0.32% of the stock is currently owned by company insiders.

DexCom Price Performance

Shares of DexCom stock opened at $71.66 on Monday. The stock's fifty day moving average is $73.09 and its 200 day moving average is $76.73. DexCom, Inc. has a one year low of $57.52 and a one year high of $132.26. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market cap of $28.10 billion, a P/E ratio of 50.11, a P/E/G ratio of 2.30 and a beta of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.